Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Cepheid’s MRSA/SA Blood Culture Test

NEW YORK (GenomeWeb News) – Cepheid said today that it has received clearance from the US Food and Drug Administration to market its Xpert MRSA/SA Blood Culture test, which detects methicillin-resistant Staphylococcus aureus and Staphylococcus aureus in blood culture bottles showing gram-positive cocci.
 
The approval follows the FDA's clearance of a version of Cepheid's test that detects MRSA/SA in skin and soft tissue infections, which the company announced on Monday.
 
Cepheid said that the Xpert MRSA/SA Blood Culture test processes positive blood culture specimens and can determine if a patient's blood is infected with MRSA or SA within one hour.
 
Currently, Cepheid said, when patients exhibit signs of systemic infections, physicians must order culture-based tests that can take 24 to 48 hours to identify the specific organism causing the infection.
 
"Same day diagnostic results for blood culture bottles growing gram-positive cocci will empower physicians to begin targeted therapy in septic patients far sooner than current culture-based methods," said Ellen Jo Baron, director of clinical microbiology laboratories for Stanford University Hospital and director of medical affairs at Cepheid, in a statement.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.